ATE389029T1 - Protease assay zur kontrolle medikamentöser therapie - Google Patents

Protease assay zur kontrolle medikamentöser therapie

Info

Publication number
ATE389029T1
ATE389029T1 AT02790358T AT02790358T ATE389029T1 AT E389029 T1 ATE389029 T1 AT E389029T1 AT 02790358 T AT02790358 T AT 02790358T AT 02790358 T AT02790358 T AT 02790358T AT E389029 T1 ATE389029 T1 AT E389029T1
Authority
AT
Austria
Prior art keywords
drug therapy
control drug
protease assay
present
concentration
Prior art date
Application number
AT02790358T
Other languages
English (en)
Inventor
Sergei Gulnik
Betty Yu
John Erickson
Martin Markowitz
Original Assignee
Tibotec Pharm Ltd
Aaron Diamond Aids Res Ct
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd, Aaron Diamond Aids Res Ct, Univ Rockefeller filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE389029T1 publication Critical patent/ATE389029T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/702Specific hybridization probes for retroviruses
    • C12Q1/703Viruses associated with AIDS
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16HIV-1, HIV-2
    • G01N2333/161HIV-1, HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40
AT02790358T 2001-11-08 2002-11-08 Protease assay zur kontrolle medikamentöser therapie ATE389029T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33111701P 2001-11-08 2001-11-08

Publications (1)

Publication Number Publication Date
ATE389029T1 true ATE389029T1 (de) 2008-03-15

Family

ID=23292681

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02790358T ATE389029T1 (de) 2001-11-08 2002-11-08 Protease assay zur kontrolle medikamentöser therapie

Country Status (8)

Country Link
US (1) US7320878B2 (de)
EP (1) EP1446498B1 (de)
JP (1) JP2005513420A (de)
AT (1) ATE389029T1 (de)
CA (1) CA2466497A1 (de)
DE (1) DE60225587T2 (de)
ES (1) ES2302860T3 (de)
WO (1) WO2003040390A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014030A1 (en) * 2002-07-18 2004-01-22 Lili Arabshahi Enzymatic assay of HIV protease inhibitors
KR20060092254A (ko) * 2003-09-23 2006-08-22 라이트 사이언시즈 코포레이션 표적화된 pdt 제제의 선택성을 증진시키는 표적 결합에의해 활성화된 일중항 산소 감광제
US20060199221A1 (en) * 2005-03-07 2006-09-07 Samad Talebpour Correction for temperature dependence assays
WO2007079392A2 (en) * 2005-12-30 2007-07-12 The Trustees Of Columbia University In The City Of New York Real-time assays of neuro-humoral to assess cardiovascular stress
US8185319B2 (en) * 2006-01-19 2012-05-22 Novx Systems Canada Inc. Method of compensation of dose-response curve of an assay for sensitivity to perturbing variables
GB201402132D0 (en) * 2014-02-07 2014-03-26 South African Nuclear Energy A method of producing ethylenedicysteine deoxyglucosamine (ECDG) or a salt thereof and its application in a kit

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1185881A (en) * 1982-02-01 1985-04-23 Jacques Degelaen ENZYMATIC PROCESS FOR THE DETERMINATION OF .beta.-LACTAM ANTIBIOTICS
DE3531778A1 (de) * 1985-09-06 1987-03-12 Behringwerke Ag Verfahren zur bestimmung von proteaseinhibitoren
EP0428000A1 (de) 1989-11-03 1991-05-22 Abbott Laboratories Fluorogene Substrate zum Nachweis von proteolytischer Enzymaktivität
US5235039A (en) 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
DK0656887T3 (da) * 1992-08-25 1999-07-05 Searle & Co Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
US5576177A (en) * 1994-03-09 1996-11-19 St. Jude Children's Research Hospital Bioassay for reverse transcriptase inhibitors
ATE217971T1 (de) 1996-01-26 2002-06-15 Virco Nv Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten
AP9801360A0 (en) 1996-01-29 1998-12-31 Virologic Incorporated Compositions and methods ofr determining anti-viral drug susceptibility and resistance and anti-viral drug screening.
JP3768304B2 (ja) 1996-10-07 2006-04-19 株式会社松井製作所 冷媒設備用のバルブ
EP0972071A4 (de) * 1997-03-07 2004-04-21 Tropix Inc Versuchsanordnung für proteaseinhibitoren
US6017723A (en) * 1998-03-27 2000-01-25 Long Island Jewish Medical Center Method for isolating inhibitors of protease activity
CA2228821A1 (en) 1998-04-16 1999-10-16 Zhibo Gan Pin method for measuring bioactive substance
PT2336134T (pt) 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
WO2001057245A2 (en) 2000-02-04 2001-08-09 K.U.Leuven Research & Development Hiv-1 resistance assay
WO2001079540A2 (en) 2000-04-18 2001-10-25 Virco Bvba Methods for measuring drug resistance
CA2419244A1 (en) * 2000-09-15 2002-03-21 Virco Bvba System and method for optimizing drug therapy for the treatment of diseases
EP1364071A2 (de) 2000-11-10 2003-11-26 Bioalliance Pharma (S.A.) Neue methode zur analyse von phänotypischen eigenschaften des humanen immunschwächevirus (hiv)

Also Published As

Publication number Publication date
EP1446498B1 (de) 2008-03-12
DE60225587T2 (de) 2009-04-02
JP2005513420A (ja) 2005-05-12
WO2003040390A3 (en) 2003-09-25
US20050221286A1 (en) 2005-10-06
ES2302860T3 (es) 2008-08-01
DE60225587D1 (de) 2008-04-24
EP1446498A2 (de) 2004-08-18
WO2003040390A2 (en) 2003-05-15
US7320878B2 (en) 2008-01-22
CA2466497A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
ATE377654T1 (de) Ubiquitin-ligase-assay
ATE485366T1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
ATE375142T1 (de) Medizinische aerosolformulierungen
DE69635671D1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
TR199800046A2 (xx) Aktif maddeler yarat�lmas� i�in n�kleik asit olu�umu.
ATE355520T1 (de) Kristallstruktur von bace und verwendungen dafür
DE69805772D1 (de) Stabilisierte mischung auf fibrinogenbasis
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
ATE389029T1 (de) Protease assay zur kontrolle medikamentöser therapie
ATE220110T1 (de) Assays und reaganzien zur identifizierung von fungiziden wirkstoffen und ihre verwendungen
DE60029413D1 (de) Enzymatische messung von mycophenolsäure
PT1147420E (pt) Inibidor de tripsina urinario para o diagnostico da sida
DE50009838D1 (de) Humanes antibiotisches protein
DK1331940T3 (da) Anvendelse af det lange pentraxin PTX3 til behandling af sygdomme forårsaget af ændret aktivering af vækstfaktoren FGF-2
DK1343896T3 (da) Lille syreoplöseligt sporeprotein og anvendelser deraf
BR0213183A (pt) Uso de ativadores gp130 em neuropatia diabética
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
HUP0204554A2 (en) Endoparasiticidal composition, preparation and use thereof
DK1095032T3 (da) Hidtil ukendte fluorescerende CYP2D-assayreagenser
ATE305612T1 (de) Reporterverbindungen und verfahren zur auffindung von hochspezifische proteaseaktivität
ATE353642T1 (de) Verwendung von hypoestoxiden als antiparasitäre mittel
ATE291435T1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE364625T1 (de) Proteine aus yaba monkey tumor virus mit modulatorischer aktivität
DE60036929D1 (de) Gentherapeutika
ATE315093T1 (de) Hcv ns2/3 fragmente und ihre verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties